close
close

Subcutaneous RNA therapy is supported by cardiac amyloidosis

Posted on by Vaseline
Subcutaneous RNA therapy is supported by cardiac amyloidosis


Cardiology Congress



The RNA interference drug can be used in cardiac ATTR amyloidosis in the HELIOS-B research study and clinical trials. The study likes to use arguments for a frühe therapy, which have been made clear by ESC-Kongress.

Related Posts

Stellantis equal weight

Stellantis equal weight

LONDON (dpa-AFX Analyzer) – The British investment bank Barclays has calculated an amount of “Overweight” on “Equal Weight” and paid a rate from 23.00 to […]